# Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer

> **NCT01721785** · — · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 307 (actual)

## Conditions studied

- Rectal Neoplasms
- Magnetic Resonance Imaging
- Neoplasms Staging

## Interventions

- **DRUG:** GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]

## Key facts

- **NCT ID:** NCT01721785
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721785, "Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT01721785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*